Pais Prescilla, Huchon Cyrille, Chevrot Audrey, Cohen Julien, Fauconnier Arnaud, Rouzier Roman, Mimouni Myriam
CHI Poissy-Saint-Germain, service de gynécologie et obstétrique, 10, rue du Champ-Gaillard, 78300 Poissy, France.
CHI Poissy-Saint-Germain, service de gynécologie et obstétrique, 10, rue du Champ-Gaillard, 78300 Poissy, France; Université Versailles-Saint-Quentin en Yvelines, EA 7285 risques cliniques et sécurité en santé des femmes, 55, avenue de Paris, 78000 Versailles, France.
Bull Cancer. 2017 Sep;104(9):721-726. doi: 10.1016/j.bulcan.2017.06.016. Epub 2017 Aug 1.
Borderline ovarian tumors are rare and can occur in young women. For these patients, a fertility sparing surgery should be discussed. Two predicting borderline ovarian tumor relapse risk models were developed in 2014 (Nomogram of Bendifallah) and 2017 (Score of Ouldamer). This study aimed to valid in an external population, these two scores using a multi-institutional BOT database.
In this bicentric and retrospective study, all consecutive patients comprising the variable nomogram documented treated between January 2006 and December 2012 for BOT in centre hospitalier de Poissy-Saint-Germain and hôpital René-Huguenin were included. A ROC model was established for each predicting scores.
Sixty-five patients were included in the study. Twelve patients showed a recurrence (19%), three of them experienced an infiltrative cancer (5%). The median time of recurrence was 25 months (range: 8-115). The concordance index for the Nomogram of Bendifallah and the Score of Ouldamer were 0.88 (IC 95% [0.78-0.98]) and 0.87 (IC 95% [0.77-0.96]) respectively.
This study from an independent population valids the Bendifallah nomogram and Ouldamer score for clinical use in predicting borderline ovarian recurrence.
卵巢交界性肿瘤罕见，可发生于年轻女性。对于这些患者，应讨论保留生育功能的手术。2014年（本迪法拉列线图）和2017年（乌尔德阿默评分）分别开发了两种预测卵巢交界性肿瘤复发风险的模型。本研究旨在利用多机构卵巢交界性肿瘤数据库，在外部人群中验证这两种评分。
在这项双中心回顾性研究中，纳入了2006年1月至2012年12月期间在普瓦西-圣日耳曼中心医院和勒内-于格南医院接受卵巢交界性肿瘤治疗且记录了可变列线图变量的所有连续患者。为每个预测评分建立了ROC模型。
65例患者纳入研究。12例患者出现复发（19%），其中3例发生浸润性癌（5%）。复发的中位时间为25个月（范围：8 - 115个月）。本迪法拉列线图和乌尔德阿默评分的一致性指数分别为0.88（95%CI[0.78 - 0.98]）和0.87（95%CI[0.77 - 0.96]）。
这项来自独立人群的研究验证了本迪法拉列线图和乌尔德阿默评分在预测卵巢交界性肿瘤复发方面的临床应用价值。
